Analisis Faktor Risiko dan Rasionalitas Penggunaan Obat pada Pasien Sirosis Hepatik

Abstract

Background: Hepatic cirrhosis remains a global health issue due to its high morbidity and mortality. Despite advances in diagnosis and treatment, the disease continues to rise, especially in developing countries. Objective: To analyze the risk factors and the rationality of drug use in patients with hepatic cirrhosis. Methods: A case–control design to analyze the risk factors and a cross-sectional design to analyze the rationality of drug use in patients with hepatic cirrhosis at Adam Malik Hospital. A total of 1568 patients (divided into 784 patients as the case group and 784 patients as the control group) for risk factors analysis and 120 patients from the case group for the rationality analysis, were randomly selected from medical records period January 2022 to December 2024. The risk factors (calculated in adjusted Odds Ratio or aOR) were analyzed using multivariate regression and the rationality was evaluated based on the clinical pathway guidelines. All statistical analyses were performed using the SPSS program version 25.0. Results: Among the participants, 75.38% of hepatic cirrhosis patients were male. The mean age of these patients was 53.97 ± 11.19 years. The three highest risk factors for hepatic cirrhosis were alcoholism (aOR = 24.452), hepatitis C (aOR = 24.172), and hepatitis B (aOR = 21.381). A total of 30.83% of 120 cirrhosis patients received rational therapy. Conclusion: This study highlighted that the three major risk factors for hepatic cirrhosis were alcoholism, hepatitis C, and hepatitis B virus infection. Only 30.83% of patients with hepatic cirrhosis received rational therapy.